Sherif I Heiba, MD

Clinical Focus

• Bone Scan
• Lung Scan
• Lymphoscintigraphy
• PET/CT Scan
• Parathyroid Scan

• Bone Scan
• Lung Scan
• Lymphoscintigraphy
• PET/CT Scan
• Parathyroid Scan

Locations

Physician Office

1190 FIFTH AVE, New York, NY, 10029

212-241-6611

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:16

Article:51

Review Article:2

Letter:1

Chapter:2

Recent Artifacts

• FDG-PET/MRI for the preoperative diagnosis and staging of peritoneal carcinomatosis: a prospective multireader pilot study
• Appropriate Use Criteria for the Use of Nuclear Medicine in Musculoskeletal Infection Imaging
• The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies
• Comparison of PET/CT and PET/MR imaging and dosimetry of yttrium-90 (⁹⁰Y) in patients with unresectable hepatic tumors who have received intra-arterial radioembolization therapy with ⁹⁰Y microspheres
• Quantitative comparison of pre-therapy ^99mTc-macroaggregated albumin SPECT/CT and post-therapy PET/MR studies of patients who have received intra-arterial radioembolization therapy with ⁹⁰Y microspheres
• Treatment of primary liver tumors and liver metastases, part 1: Nuclear medicine techniques
• Parathyroid radionuclide imaging: update
• Vagal dysfunction and small intestinal bacterial overgrowth: Novel pathways to chronic inflammation in HIV
• Evaluation of diabetic foot infection in nuclear medicine
• Successful staging of synchronous gastric cancer and diffuse large b-cell lymphoma (dlbcl) using f-18-fluorodeoxyglucose positron emission tomography/computed tomography (fdg pet/ct) based on distinctive levels of metabolic activity between the two malignancies

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Heiba did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.